BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

Post-LOE

bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride

Pfizer

ANDAORALCAPSULE

Approved

Mar 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE (bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride) by Pfizer is potassium, metronidazole and tetracycline hydrochloride is a combination of antibacterial agents (metronidazole and tetracycline hydrochloride) and bismuth subcitrate potassium [see ]. Approved for duodenal ulcer disease (active, history of within the past 5 years) to eradicate h. First approved in 2023.

Drug data last refreshed 22h ago

Mechanism of Action

potassium, metronidazole and tetracycline hydrochloride is a combination of antibacterial agents (metronidazole and tetracycline hydrochloride) and bismuth subcitrate potassium [see ].

Pharmacologic Class:

Nitroimidazole Antimicrobial

Indications (2)

duodenal ulcer disease (active history of within the past 5 years) to eradicate H

Worked on BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.